Boston Scientific has purchased endoscopic devices manufacturer EMcision, which has operations in the UK and Canada, for an undisclosed amount.
Intended to expand the Boston Scientific Endoscopy portfolio, the deal adds Habib EndoHPB probe, a bipolar radio-frequency device designed to coagulate tissue inside the gastrointestinal (GI) tract.
The endoscopic device is intended for the treatment and palliative care of pancreaticobiliary cancer patients who experience tissue ingrowth blocking ducts that facilitate draining of bile from the GI tract.
It coagulates this tissue and allows the fluids to drain, resulting in improved quality of life for patients. Stents are also used to keep the GI tract open during palliative care.
Pancreaticobiliary cancers account for nearly one million deaths annually worldwide and have limited treatment options.
While an early diagnosis improves the likelihood that a patient can meet the criteria for surgical removal of a tumour, currently only 40% of patients with cholangiocarcinoma and 20% of patients with pancreatic cancer are candidates for surgery.
EMcision products have helped thousands of patients worldwide with these difficult to treat cancers for whom surgery is not an option.
Boston Scientific Endoscopy senior vice-president and president Art Butcher said: “As we continue to search for ways to treat pancreaticobiliary cancers, we also seek to improve the quality of life for patients living with a cancer diagnosis today.
“We are committed to exploring innovative options to help increase the chance of early diagnosis, improve treatment and advance the ability to remove cancers located in challenging areas of the gastrointestinal tract.”
Boston Scientific Endoscopy division focuses on diagnosis, treatment, and management of GI and pulmonary diseases.
The firm previously expanded its business with the acquisition of EndoChoice in 2016 that integrated pathology services, infection prevention and single-use devices to its portfolio.
In addition, the firm is working on a range of devices for minimally invasive endoluminal procedures. The new devices are expected to provide an alternative to standard surgery performed to remove precancerous lesions and malignant tumours from the GI tract.